Source: Annual Congress 2009 - Infections, immunity and inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. G. Garn, D. T. Tanja, H. R. Renz (Marburg, Germany). LATE-BREAKING ABSTRACT: Advantageous therapeutic effects of a GATA-3-specific DNAzyme in comparison to corticosteroid treatment in animal models of allergic airway inflammation. Eur Respir J 2009; 34: Suppl. 53, 1604

Member's Comments

No comment yet.

Related content which might interest you: The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Corticosteroid effects on airway neuroplasticity in experimental models of asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Photobiomodulation and corticosteroid modulate pulmonary inflammation and airway reactivity in an experimental model of chronic asthma Source: International Congress 2018 – Basic pharmacology Year: 2018 Effects of budesonide/formoterol maintenance therapy on airway hyperresponsiveness and inflammation in an allergic rat model Source: Eur Respir J 2004; 24: Suppl. 48, 351s Year: 2004 Evaluation of apoptosis in inflammatory cells in a model of chronic airway inflammation in guinea pigs: effects of dexamethasone and montelukast treatments Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003 Experimental specific immunotherapy with timpol decreases allergic sensitization and airway inflammation in murine model of bronchial asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 LATE-BREAKING ABSTRACT: Inhibition of TRPA1 reduces airway inflammation and airway hyper-responsiveness in a murine model of allergic rhinitis Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 LATE-BREAKING ABSTRACT: The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Corticosteroids prevent airway remodeling in a mouse model of chronic asthma through TGF-β signaling Source: Eur Respir J 2006; 28: Suppl. 50, 225s Year: 2006 The effects of capsaicin on airway inflammation in asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 586s Year: 2004 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 Effect of budesonide/formoterol combination on an airway hyperresponsiveness and inflammation model in mice Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 LATE-BREAKING ABSTRACT: MUC1 downregulation induces corticosteroid resistance in asthma’s in vitro and in vivo models Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Effects of OVA-induced allergic airway inflammation and remodeling in mice in three distinct asthma models Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Steroid-resistant inflammation in a mouse model of severe asthma is not inhibited by the combination of theophylline and budesonide Source: International Congress 2018 – Basic pharmacology Year: 2018 Comparable efficacy of calcilytic and corticosteroid in short-term and long-term allergic asthma models in vivo Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018